مقالات پذیرفته شده در هفتمین کنگره بین المللی زیست پزشکی
Advancing Chronic Lymphoblastic Leukemia Management: A Systematic Review of Preclinical Studies on Nanotechnology-Based Diagnostics and Therapeutics
Advancing Chronic Lymphoblastic Leukemia Management: A Systematic Review of Preclinical Studies on Nanotechnology-Based Diagnostics and Therapeutics
Mojtaba Aghaei,1,*Seyed Sobhan Bahreiny,2Mohammad Mehdi abolhasani,3Mohammad Reza Dabbagh,4Ehsan Sarbazjoda,5Mohammad Sharif Sharifani,6
1. Thalassemia & Hemoglobinopathy Research Center, Health Research Institute, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran 2. Ahvaz, Iran, Azadegan St 3. Student Research Committee, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran. 4. Department of Biology, Faculty of Science, Shahid Chamran University of Ahvaz, Ahvaz, Iran. 5. Student Research Committee, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.
Introduction: Background: Chronic Lymphoblastic Leukemia (CLL) continues to pose challenges, in its diagnosis and treatment. However nanotechnology holds promise as a solution by enabling precise targeting and improving treatment effectiveness. This comprehensive review aims to evaluate studies that explore the use of nanotechnology for diagnosing and treating CLL.
Methods: Methods: To conduct this review we searched databases for preclinical studies that employed nanotechnological interventions in CLL diagnosis or therapy. We assessed the quality of the methods used in these studies analyzed their outcomes and extracted data.
Results: Results: Our findings from the experiments showed that TNF α have effects on different types of cancers. While some cytokines promote cell growth others exhibit effects. Moreover these cytokines demonstrate nuanced roles in tumor metastasis by influencing migration and invasion capabilities. The systematic review supported these multifaceted roles by highlighting context influences on tumor progression across malignancies.
Conclusion: CONCLUSION: Consequently, this systematic review highlights how nanotechnology is expanding the landscape of tools and therapeutic options for managing CLL. Preclinical evidence suggests that nanotechnology offers opportunities to advance precision medicine and improve treatment outcomes for patients, with CLL. However further research is needed through studies and clinical trials to validate these findings before they can be applied in world clinical settings.